Cerebrospinal fluid viral breakthrough in two HIV-infected subjects on darunavir/ritonavir monotherapy

References

• Heaton RK, Clifford DB, Franklin DR Jr, Woods SP, Ake C, Vaida F, . HIV-associated neurocognitive disorders persist in the era of potent antiretroviral therapy: CHARTER study. Neurology 2010;75:2087–96.
   PubMed Web of Science ®Google Scholar
• Simioni S, Cavassini M, Annoni JM, Rimbault Abraham A, Bourquin I, Schiffer V, . Cognitive dysfunction in HIV patients despite long-standing suppression of viremia. AIDS 2010;24:1243–50.
   PubMed Web of Science ®Google Scholar
• Gisslen M, Price RW, Nilsson S. The definition of HIV-associated neurocognitive disorders: are we overestimating the real prevalence? BMC Infect Dis 2011;11:356.
   PubMed Web of Science ®Google Scholar
• Hagberg L, Cinque P, Gisslen M, Brew BJ, Spudich S, Bestetti A, . Cerebrospinal fluid neopterin: an informative biomarker of central nervous system immune activation in HIV-1 infection. AIDS Res Ther 2010;7:15.
   PubMed Web of Science ®Google Scholar
• Mellgren A, Price RW, Hagberg L, Rosengren L, Brew BJ, Gisslen M. Antiretroviral treatment reduces increased CSF neurofilament protein (NFL) in HIV-1 infection. Neurology 2007;69:1536–41.
   PubMed Web of Science ®Google Scholar
• Mellgren A, Antinori A, Cinque P, Price RW, Eggers C, Hagberg L, . Cerebrospinal fluid HIV-1 infection usually responds well to antiretroviral treatment. Antivir Ther 2005; 10:701–7.
   PubMed Web of Science ®Google Scholar
• Clumeck N, Rieger A, Banhegyi D, Schmidt W, Hill A, Van Delft Y, . 96 week results from the MONET trial: a randomized comparison of darunavir/ritonavir with versus without nucleoside analogues, for patients with HIV RNA < 50 copies/ml at baseline. J Antimicrob Chemother 2011;66:1878–85.
   PubMed Web of Science ®Google Scholar
• Katlama C, Valantin MA, Algarte-Genin M, Duvivier C, Lambert-Niclot S, Girard PM, . Efficacy of darunavir/ritonavir maintenance monotherapy in patients with HIV-1 viral suppression: a randomized open-label, noninferiority trial, MONOI-ANRS 136. AIDS 2010;24:2365–74.
   PubMed Web of Science ®Google Scholar
• Gazzard B, Hill A, Anceau A. Cost-efficacy analysis of the MONET trial using UK antiretroviral drug prices. Appl Health Econ Health Policy 2011;9:217–23.
   PubMedGoogle Scholar
• Norgren N, Rosengren L, Stigbrand T. Elevated neurofilament levels in neurological diseases. Brain Res 2003;987: 25–31.
   PubMed Web of Science ®Google Scholar
• Yilmaz A, Verhofstede C, D’Avolio A, Watson V, Hagberg L, Fuchs D, . Treatment intensification has no effect on the HIV-1 central nervous system infection in patients on suppressive antiretroviral therapy. J Acquir Immune Defic Syndr 2010;55:590–6.
   PubMed Web of Science ®Google Scholar
• Maruff P, Thomas E, Cysique L, Brew B, Collie A, Snyder P, . Validity of the CogState brief battery: relationship to standardized tests and sensitivity to cognitive impairment in mild traumatic brain injury, schizophrenia, and AIDS dementia complex. Arch Clin Neuropsychol 2009;24: 165–78.
   PubMed Web of Science ®Google Scholar
• Gutmann C, Cusini A, Gunthard HF, Fux C, Hirschel B, Decosterd LA, . Randomized controlled study demonstrating failure of LPV/r monotherapy in HIV: the role of compartment and CD4-nadir. AIDS 2010;24:2347–54.
   PubMed Web of Science ®Google Scholar
• Vernazza P, Daneel S, Schiffer V, Decosterd L, Fierz W, Klimkait T, . The role of compartment penetration in PI-monotherapy: the Atazanavir-Ritonavir Monomaintenance (ATARITMO) trial. AIDS 2007;21:1309–15.
   PubMed Web of Science ®Google Scholar
• Abdulle S, Mellgren A, Brew BJ, Cinque P, Hagberg L, Price RW, . CSF neurofilament protein (NFL)—a marker of active HIV-related neurodegeneration. J Neurol 2007;254: 1026–32.
   PubMed Web of Science ®Google Scholar
• Gisslen M, Hagberg L, Brew BJ, Cinque P, Price RW, Rosengren L. Elevated cerebrospinal fluid neurofilament light protein concentrations predict the development of AIDS dementia complex. J Infect Dis 2007;195:1774–8.
   PubMed Web of Science ®Google Scholar
• Canestri A, Lescure FX, Jaureguiberry S, Moulignier A, Amiel C, Marcelin AG, . Discordance between cerebral spinal fluid and plasma HIV replication in patients with neurological symptoms who are receiving suppressive antiretroviral therapy. Clin Infect Dis 2010;50:773–8.
   PubMed Web of Science ®Google Scholar
• Eden A, Fuchs D, Hagberg L, Nilsson S, Spudich S, Svennerholm B, . HIV-1 viral escape in cerebrospinal fluid of subjects on suppressive antiretroviral treatment. J Infect Dis 2010;202:1819–25.
   PubMed Web of Science ®Google Scholar